Lakefront Biotherapeutics (LKFT)
29.52
-0.48
(-1.60%)
USD |
NASDAQ |
Oct 08, 16:00
29.52
0.00 (0.00%)
After-Hours: 20:00
Lakefront Biotherapeutics Enterprise Value : -583.55M for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | -583.55M |
| October 06, 2026 | -628.19M |
| October 05, 2026 | -615.72M |
| October 02, 2026 | -624.91M |
| October 01, 2026 | -658.39M |
| September 30, 2026 | -606.53M |
| September 29, 2026 | -615.06M |
| September 28, 2026 | -594.05M |
| September 25, 2026 | -624.25M |
| September 24, 2026 | -559.91M |
| September 23, 2026 | -536.28M |
| September 22, 2026 | -571.07M |
| September 21, 2026 | -610.47M |
| September 18, 2026 | -678.75M |
| September 17, 2026 | -655.11M |
| September 16, 2026 | -745.72M |
| September 15, 2026 | -720.11M |
| September 14, 2026 | -799.55M |
| September 11, 2026 | -792.99M |
| September 10, 2026 | -792.99M |
| September 09, 2026 | -752.28M |
| September 08, 2026 | -739.15M |
| September 04, 2026 | -682.69M |
| September 03, 2026 | -647.89M |
| September 02, 2026 | -661.68M |
| Date | Value |
|---|---|
| September 01, 2026 | -678.75M |
| August 31, 2026 | -682.03M |
| August 28, 2026 | -657.08M |
| August 27, 2026 | -620.31M |
| August 26, 2026 | -638.70M |
| August 25, 2026 | -603.24M |
| August 24, 2026 | -646.58M |
| August 21, 2026 | -662.33M |
| August 20, 2026 | -697.13M |
| August 19, 2026 | -625.57M |
| August 18, 2026 | -715.51M |
| August 17, 2026 | -746.37M |
| August 14, 2026 | -745.72M |
| August 13, 2026 | -712.23M |
| August 12, 2026 | -719.45M |
| August 11, 2026 | -666.93M |
| August 10, 2026 | -786.42M |
| August 07, 2026 | -780.51M |
| August 06, 2026 | -837.63M |
| August 05, 2026 | -840.92M |
| August 04, 2026 | -816.62M |
| August 03, 2026 | -797.58M |
| July 31, 2026 | -766.72M |
| July 30, 2026 | -738.49M |
| July 29, 2026 | -733.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 203.52B |
| ACADIA Pharmaceuticals, Inc. | 2.500B |
| Alkermes Plc | 7.860B |
| Alnylam Pharmaceuticals, Inc. | 29.69B |
| Amarin Corp. Plc | -57.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.260M |
| Revenue (Quarterly) | 14.08M |
| Total Expenses (Quarterly) | 11.82M |
| EPS Diluted (Quarterly) | 0.0349 |
| Gross Profit Margin (Quarterly) | 24.48% |
| Profit Margin (Quarterly) | 16.05% |
| Earnings Yield | 35.65% |
| Operating Earnings Yield | 34.75% |
| Normalized Earnings Yield | 45.23 |